Dr. Aleksandar Sekulic on the Hedgehog Pathway Inhibitor Vismodegib for Basal Cell Carcinoma
Aleksandar Sekulic, MD, PhD, Assistant Professor of Dermatology, Mayo Clinic, Scottsdale, AZ, discusses the Hedgehog pathway inhibitor vismodegib (Erivedge), which is approved for patients with basal cell carcinoma (BCC) and is under investigation in other tumor types. To find out more, visit http://www.onclive.com/onclive-tv/Dr-...
▶︎
Hedgehog Inhibitors Tips & Tricks
▶︎
The Hedgehog Signaling Pathway and Cancer
▶︎
Systemic Therapy in BCC
▶︎
Case 4: Infiltrative Basal Cell Carcinoma
▶︎
New Advanced Basal Cell Carcinoma Drug
▶︎
Princess Of Boogie Woogie Delights Everyone
▶︎
Sacha 'Borat' Baron Cohen Asks Melanie "What Her Price Is" | Friday Night With Jonathan Ross
▶︎
Hedgehog Signaling Pathway in Vertebrates | Purpose and Mechanism
▶︎
Welcome to hell: Inside the Colorado supermax prison
▶︎
Colin Farrell Opens Up About His Son With Angelman Syndrome | PEOPLE
▶︎
Madonna Plastic Surgeries - Surgeon Reacts
▶︎
Understanding Immunotherapy for NSCLC with PD-1 and PD-L1 Biomarkers
▶︎
Face Tattooed Killer Wade Wilson Gets Sentenced to Death
▶︎
Hedgehog Signalling Pathway
▶︎
Biosignaling | Sonic Hedgehog (Shh) Signaling Pathway
▶︎
Common cell signaling pathway
▶︎
Innovative Immunotherapy in Advanced Basal Cell Carcinoma
▶︎
The current therapeutic landscape for basal cell carcinoma
▶︎
Vismodegib in basal cell carcinoma
▶︎